Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Open accessThe DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis-driven by an imbalance of pro- and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the "vascular normalization" hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro- and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 2×
“…(VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folkman 1971; Kim et al. 1993).”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“The discovery of vascular endothelial growth factor (VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folk…”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Unlike physiological angiogenesis, blood vessel development in solid tumors is not tightly controlled, but rather occurs relentlessly (Dvorak 1986; Chung et al. 2010; Carmeliet and Jain 2011).”
BackgroundCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Cited by
Items 101–200 of 371
Towards equitable AI in oncology
Viswanathan, V. S., Parmar, V. V., & Madabhushi, A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00909-8 · Cited by 56
Zhang, H., Ren, Y. T., Tang, X., Wang, K., Liu, Y., Zhang, L. R., Li, X., Liu, P., Zhao, C., & He, J. (2015) · Scientific Reports · doi:10.1038/srep08888 · Cited by 46
“So tip the imbalance between pro-and antiangiogenic factors back toward equilibrium by mopping up some of the excessive proangiogenic factors or/and releasing some antiangiogenic factors could normalize tumor vasculature 23 .”
Linking the History of Radiation Biology to the Hallmarks of Cancer
Boss, M., Bristow, R. G., & Dewhirst, M. W. (2014) · Radiation Research · doi:10.1667/rr13675.1 · Cited by 50
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 46
Microvascular morphometrics of the hypophysis and pituitary tumors: From bench to operating theatre
Ieva, A. D., Weckman, A. M., Michele, J. D., Rotondo, F., Grizzi, F., Kovács, K., & Cusimano, M. D. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.04.009 · Cited by 46
Sorace, A. G., Quarles, C. C., Whisenant, J. G., Hanker, A. B., McIntyre, J. O., Sanchez, V. M., & Yankeelov, T. E. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3680-8 · Cited by 45
“Anti-angiogenic agents have been shown to transiently stabilize abnormal tumor vasculature through restoring the balance of the pro- and antiangiogenic factors [15, 16].”
Tumor Microenvironment of Esophageal Cancer
Schiffmann, L. M., Plum, P. S., Fuchs, H. F., Babic, B., Bruns, C. J., & Schmidt, T. (2021) · Cancers · doi:10.3390/cancers13184678 · Cited by 45
Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives
Chen, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.016 · Cited by 46
Takano, S., Ishikawa, E., Matsuda, M., Yamamoto, T., & Matsumura, A. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2620 · Cited by 45
“Taken together, the reversal effect of IFN-β on the tumor microcirculation that is considered as a concept for vascular normalization (46), could be one of the mechanisms by which IFN-β treatment exerts antiangiogenic effects in malignant glioma.”
BackgroundTan, K. F., In, L. L. A., & Kumar, P. V. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00202 · Cited by 49
Banerjee, S., Ghosh, T., Barik, S., Das, A., Ghosh, S., Bhuniya, A., Bose, A., & Baral, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110040 · Cited by 42
“In context to hostantitumor benefits such results are encouraging as recent preclinical and clinical findings suggest that vascular normalization, rather than restriction of blood flow, is necessary to maintain the surge of effector immune cells and chemical regimens for cancer therapy [38].”
BackgroundTheek, B., Baues, M., Gremse, F., Pola, R., Pechar, M., Negwer, I., Koynov, K., Weber, B., Barz, M., Jahnen‐Dechent, W., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.002 · Cited by 43
“which helps to improve the delivery of drug molecules and oxygen to tumors [17, 24-26].”
Jarrett, A. M., Bloom, M. J., Godfrey, W. H., Syed, A., Ekrut, D. A., Ehrlich, L. I. R., Yankeelov, T. E., & Sorace, A. G. (2018) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqy014 · Cited by 42
“These irregularities lead to heterogeneous blood flow, pressure and insufficient delivery of oxygen, thereby producing regions of necrosis and hypoxia throughout the tumour (Brown, 2000; Goel et al., 2012; Jain, 2013).”
BackgroundThe Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis
Li, X., Li, Y., Lu, W., Chen, M., Ye, W., & Zhang, D. (2019) · Cells · doi:10.3390/cells8121602 · Cited by 41
Immunomodulation by endothelial cells: prospects for cancer therapy
Alnaqbi, H., Becker, L. M., Mousa, M., Alshamsi, F. Y., Azzam, S. K., Veseli, B. E., Hymel, L. A., Alhosani, K. M., Alhusain, M., Mazzone, M., et al. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.002 · Cited by 41
Therapeutic Options for Metastatic Breast Cancer
Sambi, M., Qorri, B., Harless, W. W., & Szewczuk, M. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_8 · Cited by 39
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
Garcia‐Romero, N., Palacín-Aliana, I., Madurga, R., Carrión-Navarro, J., Esteban-Rubio, S., Jiménez, B., Collazo-Lorduy, A., Pérez‐Rodríguez, F. J., de Méndivil, A. O., Fernández-Carballal, C., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01610-0 · Cited by 41
Wierzbicki, M., Sawosz, E., Strojny, B., Jaworski, S., Grodzik, M., & Chwalibóg, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-33179-3 · Cited by 38
New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents
Schmitt, F., Gold, M., Rothemund, M., Andronache, I., Biersack, B., Schobert, R., & Mueller, T. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.055 · Cited by 36
Bodzioch, M., Bajger, P., & Foryś, U. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03657-9 · Cited by 36
“Contrary to our intuition, anti-angiogenic agents may have a “normalizing” effect on abnormal tumor vasculature, thus leading to an improved flow and hence improved chemotherapy delivery mechanism (Goel et al. 2012).”
BackgroundYin, J., Dong, F., An, J., Guo, T., Cheng, H., Zhang, J., & Zhang, J. (2024) · Theranostics · doi:10.7150/thno.89306 · Cited by 41
“These observations were consistent with previous findings of bevacizumab’s effect in normalizing blood flow [56], and an elevated degree of internal heterogeneity during tumor growth [57, 58].”
ResultRole of Regular Physical Exercise in Tumor Vasculature: Favorable Modulator of Tumor Milieu
Esteves, M., Monteiro, M. P., & Duarte, J. A. (2020) · International Journal of Sports Medicine · doi:10.1055/a-1308-3476 · Cited by 39
Molecular basis for pericyte-induced capillary tube network assembly and maturation
Kemp, S. S., Lin, P. K., Sun, Z., Castaño, M. A., Yrigoin, K., Penn, M. R., & Davis, G. E. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.943533 · Cited by 46
“Blockade of VEGF or its receptor in these tumor microenvironments does appear to enhance pericyte association with the capillaries and improve perfusion into the tumor, a process that has been termed tumor vessel normalization (Jain, 2005; Goel et al., 2012).”
BackgroundAngiogenesis in malignant melanoma
Felcht, M., & Thomas, M. (2015) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12580 · Cited by 40
Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies
Majewska, A., Wilkus, K., Brodaczewska, K. K., & Kiéda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020520 · Cited by 37
Piscatelli, J. A., Ban, J., Lucas, A. T., & Zamboni, W. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010114 · Cited by 36
VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells
Banerjee, K., Kerzel, T., Bekkhus, T., Ferreira, S. D. S., Wallmann, T., Wallerius, M., Landwehr, L., Agardy, D. A., Schauer, N., Malmerfeldt, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113507 · Cited by 39
László, V., Valkó, Z., Kovács, I., Ozsvar, J., Hoda, M. A., Klikovits, T., Lakatos, D., Czirók, A., Garay, T., Stiglbauer, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1507 · Cited by 36
“This is because the PDGF/PDGFR axis is crucial for pericytes and the pericyte layer has a key role in the maintenance of vessel wall stability (45).”
BackgroundPulsation-limited oxygen diffusion in the tumour microenvironment
Milotti, E., Stella, S., & Chignola, R. (2017) · Scientific Reports · doi:10.1038/srep39762 · Cited by 33
“(12), however here there is a faster-than-exponential falloff because of the r 1/ dependence.”
BackgroundMultifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Portillo, A. L., Monteiro, J. K., Rojas, E. A. P., Ritchie, T. M., Gillgrass, A. E., & Ashkar, A. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286750 · Cited by 35
Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors
Bagley, A. F., Scherz‐Shouval, R., Galie, P. A., Zhang, A. Q., Wyckoff, J. B., Whitesell, L. J., Chen, C. S., Lindquist, S. L., & Bhatia, S. N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0325 · Cited by 31
“The anti-angiogenesis antibodies trastuzumab, bevacizumab, and cediranib normalize tumor vasculature and thereby improve tumor blood flow.[9-12] Transvascular transport is enhanced by vascular endothelial growth factor (VEGF), tumor necrosis factor alpha (TNFα), interleukin 1 (IL-1), histamine, and tumor-penetrating p…”
Syed, A., Woodall, R. T., Whisenant, J. G., Yankeelov, T. E., & Sorace, A. G. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.008 · Cited by 34
Koyama, S., Matsunaga, S., Imanishi, M., Maekawa, Y., Kitano, H., Takeuchi, H., & Tomita, S. (2017) · Scientific Reports · doi:10.1038/srep45621 · Cited by 31
Park, S., Oh, J. H., Park, D. J., Zhang, H., Noh, M., Kim, Y., Kim, Y.-S., Kim, H., Kim, Y., Ha, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620166 · Cited by 31
“Immunosuppression created by the abnormal TME vasculature cannot be modified by anti-PD-1 therapy (17), which may restore TME structure but does not abolish blood vessels (18).”
BackgroundWei, F., Su, Y., Quan, Y., Li, X., Zou, Q., Zhang, L., Li, S., Jiang, M., Lin, G., Liang, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2757 · Cited by 31
MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kieda, C. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0231-4 · Cited by 30
“Indirect inhibitors of angiogenesis target tumor cell oncogenes such as HER-2, the PI3K-AKT-mTOR axis, Ras and epidermal growth factor receptor, and include endocrine therapies and metronomic chemotherapy (Goel et al. 2012).”
BackgroundWilliams, J. P., Calvi, L. M., Chakkalakal, J. V., Finkelstein, J. N., O’Banion, M. K., & Puzas, E. J. (2016) · Radiation Research · doi:10.1667/rr14473.1 · Cited by 31
“have promulgated the suggestion that normalizing the tumor vasculature will improve therapeutic outcome (192, 193).”
Chen, T. W., Dai, M., Tseng, L., Chen, S., Chao, T., Chao, T., Chang, Y., Chiu, C., Liu, C.-T., Lin, C., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5456 · Cited by 30
Kaffas, A. E., Nofiele, J. T., Giles, A., Cho, S., Liu, S. K., & Czarnota, G. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093888 · Cited by 30
“It is also possible that radiation may be pruning less mature endothelial cells, leading to an enhanced vascular architecture and increased blood flow [34].”
BackgroundLenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Pan, J., Zhu, S., Huang, J., Liang, J., Zhang, D., Zhao, X., Ding, H., Li, Q., Shi, C., Luo, L., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00524 · Cited by 28
“The structural features of normalized tumor vessels include reduced vessel diameter, increased pericyte coverage or proximity, and normalized basement membrane, and their functional features include improved oxygenation, reduced permeability or interstitial fluid pressure, and improved delivery of drugs or systemicall…”
BackgroundMonocytes and Macrophages in Cancer: Unsuspected Roles
Gouveia-Fernandes, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_9 · Cited by 35
Nanomedicine: The Promise and Challenges in Cancer Chemotherapy
Naguib, Y. W., & Cui, Z. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8739-0_11 · Cited by 29
The potential roles of dopamine in malignant glioma
Lan, Y., Wang, X., Xing, J., Lou, J., Ma, X., & Zhang, B. (2016) · Acta Neurologica Belgica · doi:10.1007/s13760-016-0730-2 · Cited by 28
Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors
Tadeo, I., Bueno, G., Berbegall, A. P., Fernández-Carrobles, M. M., Castel, V., García‐Rojo, M., Navarro, S., & Noguera, R. (2016) · Oncotarget · doi:10.18632/oncotarget.7661 · Cited by 27
“com/oncotarget permeable and tortuous and leads to reduced fluid and protein extravasation into the interstitium, resulting in a decrease in tumor interstitial pressure [27, 28].”
BackgroundEmerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
“Based on the vessel normalization effects of anti-angiogenic therapies at lower doses, which result in increased pericyte coverage, and improved tumor perfusion and oxygenation [229], recent evidence suggests that anti-angiogenic treatment may be an effective modality to potentiate the efficacy of immunotherapies [27,…”
BackgroundSelf-citationThe potential for remodelling the tumour vasculature in glioblastoma
Brighi, C., Puttick, S. G., Rose, S., & Whittaker, A. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.001 · Cited by 29
Hafny‐Rahbi, B. E., Brodaczewska, K. K., Collet, G., Majewska, A., Klimkiewicz, K., Delalande, A., Grillon, C., & Kiéda, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16399 · Cited by 27
The Effects of Physical Exercise on Tumor Vasculature: Systematic Review and Meta-analysis
Esteves, M., Monteiro, M. P., & Duarte, J. A. (2021) · International Journal of Sports Medicine · doi:10.1055/a-1533-1876 · Cited by 28
Truelsen, S. L. B., Mousavi, N., Wei, H., Harvey, L., Stausholm, R., Spillum, E., Hagel, G., Qvortrup, K., Thastrup, M., Harling, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253258 · Cited by 26
“Effective anti-angiogenic treatment enhances the vascular circulation and decreases the interstitial pressure of the tumour which improves the delivery of both nutrients and chemotherapeutics [12].”
BackgroundQuan, Y., He, J., Zou, Q., Zhang, L., Sun, Q., Huang, H., Li, W., Xie, K., & Wei, F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007080 · Cited by 30
Choi, Y. S., Jang, H., Gupta, B., Jeong, J.-H., Ge, Y., Yong, C. S., Kim, J. O., Bae, J., Song, I., Kim, I., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00952-9 · Cited by 28
Challenges and Opportunities for Childhood Cancer Drug Development
Houghton, P. J., & Kurmasheva, R. T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016972 · Cited by 27
“While antiangiogenic agents can “normalize” tumor vasculature, reduce interstitial pressure, and enhance uptake of cytotoxic agents (Goel et al., 2012; Jain, 2014), antiangiogenic drugs may also have”
BackgroundJiang, Y., Guo, Y., Hao, J., Guenter, R. E., Lathia, J. D., Beck, A. W., Hattaway, R., Hurst, D. R., Wang, Q. J., Liu, Y., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02308-6 · Cited by 25
Jordan, A. M., Drake, R. J. G., & Hodivala‐Dilke, K. (2025) · Physiological Reviews · doi:10.1152/physrev.00046.2024 · Cited by 31
Raman, F., Scribner, E. Y., Saut, O., Wenger, C., Colin, T., & Fathallah‐Shaykh, H. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146617 · Cited by 26
Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse
Mukwaya, A., Mirabelli, P., Lennikov, A., Thangavelu, M., Ntzouni, M. P., Jensen, L. D., Peebo, B. B., & Lagali, N. (2019) · Angiogenesis · doi:10.1007/s10456-019-09679-9 · Cited by 26
Harnessing the potential of multimodal radiotherapy in prostate cancer
Philippou, Y., Sjoberg, H. T., Lamb, A. D. G., Camilleri, P., & Bryant, R. J. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0310-3 · Cited by 26
Lu, Z., Verginadis, I. I., Kumazoe, M., Castillo, G. M., Yao, Y., Guerra, R. E., Bicher, S., You, M., McClung, G., Qiu, R., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn0904 · Cited by 26
“Deficient perfusion of tumor tissues poses problems for the efficacy of therapeutics ( 37 , 38 ); thus, we sought to investigate whether dCNP can be combined with anticancer therapeutic approaches such as chemotherapy, radiotherapy, and immune therapy to bring about additional benefits.”
BackgroundLobo, M. R., Green, S. C., Schabel, M. C., Gillespie, G. Y., Woltjer, R. L., & Pike, M. M. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not119 · Cited by 23
Jain, H. V., & Jackson, T. L. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-017-0273-6 · Cited by 24
“…that anti-angiogenic therapy aimed at VEGFR2 initially improves both the structure and function of tumor vessels; however, continued or aggressive regimes result in a vascular supply that is inadequate to support delivery of additional therapeutic agents (Goel et al. 2012; Lin and Sessa 2004).”
BackgroundMR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment
Yang, J., Liao, C., Liu, Y., Yang, G., Ke, T., Ding, Y., & Li, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.22600 · Cited by 24
“Bevacizumab, an antibody to vascular endothelial growth factor (VEGF), has been investigated as a targeted mechanism to normalize vasculature in both preclinical and some clinical studies [8, 9].”
BackgroundGarcía, M., Martinez–Villacampa, M., Santos, C., Navarro, V., Teulé, À., Losa, F., Pisa, A., Cambray, M., Soler, G., Lema, L., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1052-0 · Cited by 23
“Following the vascular normalization hypothesis [9] although speculative, the advantage conferred by the treatment with bevacizumab plus chemotherapy in the treatment of colon cancer patients could be due to increased tumour cell sensitivity to the action of the chemotherapy or even the better delivery of chemotherapy…”
BackgroundNanoparticles for tumor targeting
Jiang, T., Jin, K., Liu, X., & Pang, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101914-6.00008-9 · Cited by 30
Bloom, M. J., Jarrett, A. M., Triplett, T., Syed, A., Davis, T., Yankeelov, T. E., & Sorace, A. G. (2020) · BMC Cancer · doi:10.1186/s12885-020-06868-4 · Cited by 23
Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
Yang, G., & Li, L. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0023-8 · Cited by 23
Wang, Q., Zhong, W., Xiao, Y., Lin, G., Lu, J., Xu, L., Zhang, G., Liu, A., Du, J., & Wu, B. (2024) · Cancer Science · doi:10.1111/cas.16400 · Cited by 24
Han, M., Sun, Y., Zhao, W., Xiang, G., Wang, X., Jiang, Z., Xue, Z., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025286 · Cited by 23
“The abnormal structure and hyperpermeability of the tumor vessels induce aberrations in fluid dynamics and oxygen supply, which can provoke the growth of GBM or other cancer cells and reduce the effect of cytotoxic drugs (5, 7).”
BackgroundCapkin, A. A., Demir, S., Menteşe, A., Bulut, Ç., & Ayar, A. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1722-7 · Cited by 21
Chebib, R., Verlingue, L., Cozic, N., Faron, M., Burtin, P. C., Boige, V., Hollebecque, A., & Malka, D. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.07.004 · Cited by 22
Wong, A. L. A., Sundar, R., Wang, T., Ng, T.-C., Zhang, B., Tan, S., Soh, I., Pang, A. S. L., Tan, C., Ow, S. G. W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11596 · Cited by 22
“However, high or prolonged dosing subsequently causes excessive pruning and blood vessel destruction, impeding intra-tumoral chemotherapy delivery when administered concurrently [7, 8].”
BackgroundSelf-citationvon der Lippe Gythfeldt, H., Lien, T., Tekpli, X., Silwal‐Pandit, L., Borgen, E., Garred, Ø., Skjerven, H., Schlichting, E., Lundgren, S., Wist, E., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33108 · Cited by 20
“Blocking VEGF by the monoclonal antibody bevacizumab affects vascular function and has been proposed to cause inhibition of new-vessel formation and normalization of the remaining vasculature, resulting in an improved and more uniform delivery of drugs.(43) This may certainly enhance the clinical response observed in…”
BackgroundA Distinct Mechanism of Vascular Lumen Formation in Xenopus Requires EGFL7
Charpentier, M. S., Tandon, P., Trincot, C. E., Koutleva, E. K., & Conlon, F. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116086 · Cited by 22
“"Vessel normalization" aims to remodel the tumor vasculature by restoring endothelial cell function and inducing vessel maturation thereby enabling efficient blood flow and minimizing dissemination of cancer cells to sites throughout the body [85,86].”
BackgroundAnti-VEGF Therapy in Cancer: A Double-Edged Sword
Gardner, V., Madu, C. O., & Lu, Y. W. (2017) · InTech eBooks · doi:10.5772/66763 · Cited by 26
“In this state, it is easier to deliver cytotoxic drugs from conventional chemotherapy to the tumor in a treatment schedule that takes advantage of the window presented by antiangiogenic agents given in low doses [106].”
BackgroundShan, Y., Wang, B., & Zhang, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21517 · Cited by 20
Biophysical and biochemical aspects of immune cell–tumor microenvironment interactions
Benmelech, S., Le, T., McKay, M., Nam, J., Subramaniam, K. V., Tellez, D., Vlasak, G., & Mak, M. (2024) · APL Bioengineering · doi:10.1063/5.0195244 · Cited by 19
Kim, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16908-4_3 · Cited by 21
Wang, Q., Xiang, Q., Yu, L., Hu, T., Chen, Y., Wang, J., Nie, X., & Cheng, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01545 · Cited by 26
Ayuso-Íñigo, B., Méndez-García, L., Pericacho, M., & Muñoz‐Félix, J. M. (2021) · Cancers · doi:10.3390/cancers13215412 · Cited by 22
“the tumor vasculature, especially when used at a low dose [23,24].”
BackgroundFinegold, M. J., & Lopez-Terrada, D. H. (2014) · Springer eBooks · doi:10.1007/978-3-642-54053-0_14 · Cited by 19
Chung, T. K., Warram, J. M., Day, K. E., Hartman, Y. E., & Rosenthal, E. L. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1016664 · Cited by 19
“6 Bevacizumab, an antibody to the VEGF ligand, has been investigated as a targeted mechanism to normalize vessels in both preclinical and some clinical studies.(7) While these studies support the principle of vessel normalization to facilitate delivery of small molecules,8,9 very few studies demonstrate improved deliv…”
BackgroundBidirectional regulation of i-type lysozyme on cutaneous wound healing
Yang, Y., Zhang, C., Cao, Y., Qu, Y., Li, T., Yang, T., Geng, D., & Sun, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110700 · Cited by 18
EPA and DHA Fatty Acids Induce a Remodeling of Tumor Vasculature and Potentiate Docetaxel Activity
Goupille, C., Vibet, S., Frank, P. G., & Mahéo, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144965 · Cited by 17
ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression
Sheldon, H., Bridges, E., Silva, I., Masiero, M., Favara, D. M., Wang, D., Leek, R., Snell, C. E., Roxanis, I., Kreuzer, M., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0171 · Cited by 17
“A similar concept is behind the idea that antiangiogenic therapies have the ability to induce “vascular normalization” and create vessels that are more capable of delivering anticancer therapies as well as reducing the rate of metastasis (45).”
BackgroundSjoberg, H. T., Philippou, Y., Magnussen, A., Tullis, I. D. C., Bridges, E., Chatrian, A., Lefebvre, J., Tam, K. H., Murphy, E. A., Rittscher, J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01450-6 · Cited by 16
Clinical Imaging of Tumor Angiogenesis
Patel, N., Harris, A. L., Gleeson, F. V., & Vallis, K. A. (2012) · Future Oncology · doi:10.2217/fon.12.136 · Cited by 16
“Antiangiogenic therapies can also induce structural, functional and molecular changes in tumor vessels that actually improve blood flow or ‘normalize’ it [9].”
Wu, J., & Starr, S. (2014) · Future Oncology · doi:10.2217/fon.13.272 · Cited by 17
Computational Systems Biology for the VEGF Family in Angiogenesis
Weddell, J. C., & Imoukhuede, P. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99548-6 · Cited by 18
Potential Regulatory Roles of GRK2 in Endothelial Cell Activity and Pathological Angiogenesis
Kuai, J., Han, C., & Wei, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698424 · Cited by 15
Close, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.16.6 · Cited by 16
Symonds, L. K., Jenkins, I., Linden, H. M., Kurland, B. F., Gralow, J. R., Gadi, V., Ellis, G. K., Wu, Q. V., Rodler, E. T., Chalasani, P., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.009 · Cited by 18
Amine‐weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors
Cho, N. S., Hagiwara, A., Yao, J., Nathanson, D. A., Prins, R. M., Wang, C., Raymond, C., Desousa, B. R., Divakaruni, A. S., Morrow, D., et al. (2022) · NMR in Biomedicine · doi:10.1002/nbm.4785 · Cited by 18
“The use of antiangiogenic agents is one approach to modify the tumor microenvironment, transiently “normalizing” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and therapeutic delivery.(78,79) Presumably, normalization of the tumor vasculature should also reduce tumor aci…”
BackgroundImpact of metronomic neoadjuvant chemotherapy on early tongue cancer
Kina, S., Nakasone, T., Kinjo, T., Maruyama, T., Kawano, T., & Arasaki, A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3141-4 · Cited by 16
Alaoui‐Lasmaili, K. E., Djermoune, E., Tylcz, J., Meng, D., Plénat, F., Thomas, N., & Faivre‐Fiorina, B. (2016) · Angiogenesis · doi:10.1007/s10456-016-9536-3 · Cited by 16
Complex Effects of Tumor Microenvironment on the Tumor Disposition of carrier-mediated Agents
Lucas, A. T., Price, L., Schorzman, A. N., & Zamboni, W. C. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0101 · Cited by 15
Amgen's angiopoietin blocker fails in ovarian cancer
Sheridan, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0115-5 · Cited by 17
From Nanoparticle Design to Clinical Translation in Cancer Therapy
Puiggalí, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052253 · Cited by 16
Application of nanoparticles to target tumor blood vessels as a promising cancer treatment strategy
Lorenc, P., Dams‐Kozlowska, H., Guzniczak, N., & Florczak, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118038 · Cited by 15
Novel Therapeutic Strategies for Solid Tumor Based on Body’s Intrinsic Antitumor Immune System
Duan, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489979 · Cited by 14
Metadata
- Authors
- Goel, S., Wong, A. H.-K., & Jain, R. K.
- Affiliations
- Harvard University (US)
- ORCID
- Goel, S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-18
- Volume
- 2
- Issue
- 3
- Pages
- a006486-a006486
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282493
- OpenAlex
- W2115852392
- Cited by
- 352
- References
- 191
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 22 · 2023: 27 · 2022: 18 · 2021: 31 · 2020: 30 · 2019: 23 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 28 · 2014: 21 · 2013: 13 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- US-UK Fulbright Commission
- Fulbright Australia
- National Institutes of Health (W81XWH, CA126642, CA115767, R01-CA85140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, R01 CA 85140, R01CA085140, P01CA080124, R01CA126642, P01-CA-80124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vascular normalization, pathological angiogenesis, anti-angiogenic therapy, tumor vasculature, tumor microenvironment, solid tumors
- MeSH terms
- Cytotoxins, Humans, Macular Degeneration, Neoplasms, Neuroma, Acoustic, Psoriasis, Telangiectasia, Hereditary Hemorrhagic, Disease Progression, Neovascularization, Physiologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Angiopoietin-2, Microvessels, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.